scholarly article | Q13442814 |
P356 | DOI | 10.1155/2013/687176 |
P8608 | Fatcat ID | release_5dke65rgrzeotdqbw2slr6qi7m |
P932 | PMC publication ID | 3730211 |
P698 | PubMed publication ID | 23956848 |
P5875 | ResearchGate publication ID | 255976849 |
P50 | author | Qing Ma | Q42972374 |
P2093 | author name string | Gene D Morse | |
Joshua R Sawyer | |||
Chiu-Bin Hsiao | |||
James M Mikula | |||
P2860 | cites work | Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel | Q56973152 |
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study | Q83204180 | ||
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia | Q83711798 | ||
Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks | Q34447780 | ||
High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. | Q35965800 | ||
Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy | Q36428713 | ||
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data | Q36658969 | ||
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs | Q37345610 | ||
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure | Q37693158 | ||
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. | Q43199280 | ||
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial | Q43265110 | ||
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. | Q43265351 | ||
Resistance profile of darunavir: combined 24-week results from the POWER trials | Q46712726 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | darunavir | Q3765251 |
P304 | page(s) | 687176 | |
P577 | publication date | 2013-07-17 | |
P1433 | published in | AIDS Research and Treatment | Q26854014 |
P1476 | title | Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients | |
P478 | volume | 2013 |
Search more.